Trial · NCT00908466
Sirolimus as Therapeutic Approach to Uveitis
NCT00908466, Phase 1, Completed, Johns Hopkins University; results first posted 2018-08-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sirolimus as Therapeutic Approach to Uveitis. Trials, record NCT00908466. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00908466
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sirolimus as Therapeutic Approach to Uveitis
- NCT number
- NCT00908466
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 30 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Interventions
- Sirolimus (rapamycin), Sirolimus (rapamycin)
- First posted
- 2009-05-25
- Last updated
- 2018-08-20
- Results first posted
- 2018-08-20
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH) | 6 months | Vitreous Haze is calculated using a 9 step photographic haze in uveitis patients using fundus photograph |
| Secondary | Change From Baseline VA by ETDRS | 6 and 12 months |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH) | 6 months | participants | NUMBER | |
| SECONDARY | Change From Baseline VA by ETDRS | 6 and 12 months |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH) | Intravitreal Injection | 4 | participants | ||
| Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH) | Subconjunctival Injection | 4 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intravitreal Injection | 15 | |
| Overall Study | STARTED | Subconjunctival Injection | 15 | |
| Overall Study | COMPLETED | Intravitreal Injection | 14 | |
| Overall Study | COMPLETED | Subconjunctival Injection | 14 | |
| Overall Study | NOT COMPLETED | Intravitreal Injection | 1 | |
| Overall Study | NOT COMPLETED | Subconjunctival Injection | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Inflammation at the injection site | Eye disorders | Intravitreal Injection | 0 | 15 | 0 |
| other | Inflammation at the injection site | Eye disorders | Subconjunctival Injection | 6 | 15 | 7 |
| serious | Serious Ocular Adverse Event | Eye disorders | Intravitreal Injection | 1 | 15 | 1 |
| serious | Serious Ocular Adverse Event | Eye disorders | Subconjunctival Injection | 0 | 15 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intravitreal Injection | ||
| Total, all-cause mortality | Subconjunctival Injection | ||
| Total, other adverse events | Intravitreal Injection | 0 | 15 |
| Total, other adverse events | Subconjunctival Injection | 6 | 15 |
| Total, serious adverse events | Intravitreal Injection | 1 | 15 |
| Total, serious adverse events | Subconjunctival Injection | 0 | 15 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25918559 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Intravitreal Injection vs Subconjunctival Injection: Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH) | Trial comparisons |
| Intravitreal Injection vs Subconjunctival Injection: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00908466
GET https://conductscience.org/api/trials/v1/NCT00908466/registered